TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Topotecan clearance (CL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Microalbuminuria (ACR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Glycated hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30% pain reduction of worst reported pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: characteristic pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: graded chronic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 17-BMP area under the concentration-time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from Grade 2+ GI toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Circulating IL-10 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of significant gastric lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Development of ulcers
Endpoint domain: Adverse events/effects
Primary endpoint: Satisfaction with childbirth
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of support actions performed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of unplanned hospitalizations for cardiovascular causes or death for cardiovascular causes or progression to permanent AF
Endpoint domain: Mortality/survival
Primary endpoint: serum iPTH concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Initiation of additional perioperative communication
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Coronary flow measured by TFC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Transient heart block
Endpoint domain: Adverse events/effects
Primary endpoint: Cytopathologic study results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum uroflow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Madsen score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life measures (acceptability item)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean number of outbreaks per year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean duration of outbreaks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: absolute bioavailability of sublingual ketamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time of the peak plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: local tolerability of the ketamine wafer
Endpoint domain: Adverse events/effects
Primary endpoint: Total colonoscopy time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Cardiac efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Geometric mean titer of anti-HAV antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Under-triage of severely injured patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of eyes gaining ≥15 ETDRS letters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight maintenance at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PTPmod
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Morbidity/mortality events
Endpoint domain: Mortality/survival
Primary endpoint: general health and vitality
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: 3-year cumulative survival rates of implants
Endpoint domain: Mortality/survival
Primary endpoint: Residual bone height (RBH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Marginal bone level (MBL) after 3 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of BME in the OA hip as measured by MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sedation score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Delayed postpolypectomy bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Postprocedure STT measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postprocedure PNIF values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of crusting
Endpoint domain: Adverse events/effects
Primary endpoint: Left ventricular ejection fraction reductions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: stoma complications
Endpoint domain: Adverse events/effects
Primary endpoint: post-closure surgical complications
Endpoint domain: Adverse events/effects
Primary endpoint: rate of bowel incontinence
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma clearance (CL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration for 50% effect (C50)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time to BIS 50
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in AIx
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Incremental area under blood glucose curves
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Efficacy against existing infestations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Geometric mean live tick counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: composite endpoint of all-cause death, any MI, and all-cause revascularization
Endpoint domain: Mortality/survival
Primary endpoint: very late definite ST
Endpoint domain: Adverse events/effects
Primary endpoint: ST-associated clinical events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of obstetric bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of postoperative adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Probability of drinking during alcohol withdrawal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DTA (Defense Thought Activation)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Triceps skinfold values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of adverse effects (respiratory infection and diarrhea)
Endpoint domain: Adverse events/effects
Primary endpoint: Post-exercise tryptophan levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of URTI symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: AUC of RH response after ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peak FBF response after ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Scores of Watian drinking water test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relapse rate in remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ≥15-letter best-corrected visual acuity gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean average change in central retinal thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physician's Global Assessment scores indicative of no or mild disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Inflammatory Bowel Disease Questionnaire scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Discontinuation of infliximab infusions
Endpoint domain: Adverse events/effects
Primary endpoint: NPZ‐8 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Renal clearance of NMN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: word recall performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Likelihood of continuing conventional therapy at 1 year
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Nucleosome concentration in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peptide-YY AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: carbon dioxide emissions per randomized patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: D-dimer levels change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Headache during packing and removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of bleeding during removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ease of removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate (> or = 50% reduction in NPI-behavioral subscale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity for anterior circulation aneurysms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity for aneurysms </=5 mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity for aneurysms >5 mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal fall in FEV1 during LAR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: systemic peripheral resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: vagal sinus activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of CD4(+) and CD8(+) T cells responding to HIV‐1 Gag antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Arthropathy incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Five-year failure-free survival rates
Endpoint domain: Mortality/survival
Primary endpoint: Mean change in CFS from baseline to month 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with ≥25% improvement in VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with improvements of ≥2 grades in CFS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emerging mutations at NS3 positions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of coping-related behaviors
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: positive facial affect
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: active engagement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Blood Pressure Lowering
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of patients reporting mild to no pain after 2 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean pain intensity difference from baseline at 2 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CP intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quick DASH reduction
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Initiation of regular contraception
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Incidence of unplanned pregnancy
Endpoint domain: Mortality/survival
Primary endpoint: Laryngoscopy attempts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Lung deflation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in serum sodium (sNa)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment success (normal sNa or increase of ≥6 mEq/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: log LDL/HDL cholesterol ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: log non-HDL cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Microcirculation improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain relief measured by VRS-4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attentional functioning
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Prevention of malaria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Prevention of anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elevated high-density lipoprotein (HDL) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improved glucose homeostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Disappearance of lesions on CT scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Seizure recurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the concentration-time curve (AUC0-24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of spasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean quality‐adjusted life years per patient
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pain immediately prior to IUD insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain after IUD insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Faecal bifidobacteria levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Enterobacteria levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall caloric intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity for detecting malignancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: SLE Activity Measure (SLAM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SLE Disease Activity Index (SLEDAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction in worst pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SF-12 interference with social activities
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Reduction in frequency and disruptiveness of agitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of pancreatic sepsis
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of multiple organ dysfunction syndrome
Endpoint domain: Adverse events/effects
Primary endpoint: cavity closure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Balance Error Scoring System
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to maximal neuromuscular blockade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ED95 values of rocuronium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma AAL levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SBI reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HAQ deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physician global score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anterior cruciate ligament strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Skin test positivity rate to Trichophyton extract
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sensitivity to T. rubrum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of severe asthma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: adjusted postintervention chair‐rise times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative infective complications
Endpoint domain: Adverse events/effects
Primary endpoint: Epi-induced plasma lactate level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Median sleep latency
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Incidence of venous thromboembolism
Endpoint domain: Mortality/survival
Primary endpoint: Death due to venous thromboembolism
Endpoint domain: Mortality/survival
Primary endpoint: Knee Society Score (KSS) improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Range of Motion (ROM) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Water-retaining capacity of the skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: PCI success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: complete revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: rate of death or nonfatal myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: Seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insertion depth in centimeters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Counted folds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal delta values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: expired cumulative amount of 13C
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to maximal delta value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CK concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: moment of peak lactate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perception of recovery
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Duration from the beginning of the active phase to delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hypnotic use reduction
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: daytime functioning improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: mean lesion response rate at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain and disability index scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: asthma symptom-medication score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cutaneous reactivity to allergen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: bronchial reactivity to allergen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Renal artery visualization scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of one or more adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Post-test score improvement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: incidence of postoperative nasal bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: need for medical assistance
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time required for performing the block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Onset of subjective analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Onset of sensory block to pinprick
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: treatment effect for AM-111 in profound ISSNHL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Interference with normal daily activity due to SAMS
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time to additional breast cancer events
Endpoint domain: Mortality/survival
Primary endpoint: Pain scores during TFNAB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of stroke
Endpoint domain: Mortality/survival